Neutral
Eli Lilly (LLY) collaborates with BioArctic to advance Alzheimer's treatment.
Eli Lilly has entered a research collaboration with BioArctic to develop a new Alzheimer's treatment combining BioArctic's BrainTransporter technology with an Eli Lilly drug candidate. This partnership aims to enhance the delivery of Alzheimer's therapies to the brain, expanding Lilly's neurology research efforts.
Key points
- Eli Lilly and BioArctic announce a collaboration to develop an Alzheimer's treatment.
- The partnership focuses on improving delivery of Alzheimer's therapies to the brain.
- This collaboration adds to Eli Lilly's neurodegenerative disease pipeline.
Sources
AI-generated from public news sources. Not financial advice.
